Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes
Open Access
- 1 September 2020
- journal article
- research article
- Published by Elsevier in Kidney International
- Vol. 98 (3) , 769-777
Abstract
No abstract availableKeywords
Funding Information
- Janssen Research & Development
This publication has 40 references indexed in Scilit:
- Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 DiabetesJACC: Heart Failure, 2020
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trialThe Lancet Diabetes & Endocrinology, 2019
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2019
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trialsThe Lancet, 2019
- Renal, metabolic and cardiovascular considerations of SGLT2 inhibitionNature Reviews Nephrology, 2016
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes MellitusCirculation, 2016
- Empagliflozin and Progression of Kidney Disease in Type 2 DiabetesNew England Journal of Medicine, 2016
- Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetesEuropean Heart Journal, 2015
- Mediation AnalysisAnnual Review of Psychology, 2007
- Surrogate End Points in Clinical Trials: Are We Being Misled?Annals of Internal Medicine, 1996